Antimetastatic Effect of Epigenetic Drugs, Hydralazine and Valproic Acid, in Ras-transformed NIH 3T3 Cells

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Dec 26

PMID 30584338

Citations 3

Authors

Enrique Perez-Cardenas

Lucia Taja-Chayeb

Catalina Trejo-Becerril

Jose Chanona-Vilchis

Alma Chavez-Blanco

Guadalupe Dominguez-Gomez

Elizabeth Langley

Alejandro Garcia-Carranca

Alfonso Duenas-Gonzalez

Affiliations

Soon will be listed here.

Abstract

Introduction: Metastasis involves the accumulation of genetic and epigenetic alterations leading to activation of prometastatic genes and inactivation of antimetastatic genes. Among epigenetic alterations, DNA hypermethylation and histone hypoacetylation are the focus of intense translational research because their pharmacological inhibition has been shown to produce antineoplastic activity in a variety of experimental models.

Aims: This study aimed to evaluate the antimetastatic effect of the DNA-methylation inhibitor, hydralazine, and the histone deacetylase inhibitor, valproic acid.

Methods: NIH 3T3- murine cells were treated with hydralazine and valproic acid to evaluate their effects upon cell proliferation, cell motility, chemotaxis, gelatinase activity, and gene expression. Lung metastases were developed by intravenous injection of NIH 3T3- cells in BALB/c nu/nu mice and then treated with the drug combination.

Results: Treatment induced a growth-inhibitory effect on NIH 3T3- cells, showed a trend toward increased gelatinase activity of MMP2 and MMP9, and inhibited chemotaxis and cell motility. The combination led to a strong antimetastatic effect in lungs of nude mice.

Conclusion: Hydralazine and valproic acid, two repositioned drugs as epigenetic agents, exhibit antimetastatic effects in vitro and in vivo and hold potential for cancer treatment.

Citing Articles

Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp.

Hijazi M, Gessner A, El-Najjar N Cancers (Basel). 2023; 15(12).

PMID: 37370809 PMC: 10296024. DOI: 10.3390/cancers15123199.

Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior.

Kumar V, Nambiar R, De Souza C, Nguyen A, Chien J, Lam K Cells. 2022; 11(9).

PMID: 35563709 PMC: 9102449. DOI: 10.3390/cells11091403.

DNA Methylation as a Therapeutic Target for Bladder Cancer.

Nunes S, Henrique R, Jeronimo C, Paramio J Cells. 2020; 9(8).

PMID: 32784599 PMC: 7463638. DOI: 10.3390/cells9081850.

References

Graff J, Gabrielson E, Fujii H, Baylin S, Herman J . Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem. 2000; 275(4):2727-32. DOI: 10.1074/jbc.275.4.2727. View

Zhu W, Lakshmanan R, Beal M, Otterson G . DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2001; 61(4):1327-33. View

Hartsough M, Clare S, Mair M, Elkahloun A, Sgroi D, Osborne C . Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res. 2001; 61(5):2320-7. View

Primeau M, Gagnon J, Momparler R . Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer. 2002; 103(2):177-84. DOI: 10.1002/ijc.10789. View

Sato N, Maehara N, Su G, Goggins M . Effects of 5-aza-2'-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst. 2003; 95(4):327-30. DOI: 10.1093/jnci/95.4.327. View

Gagnon J, Shaker S, Primeau M, Hurtubise A, Momparler R . Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. Anticancer Drugs. 2003; 14(3):193-202. DOI: 10.1097/00001813-200303000-00002. View

Zhu W, Otterson G . The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents. 2003; 3(3):187-99. DOI: 10.2174/1568011033482440. View

Arguello-Ramirez J, Perez-Cardenas E, Delgado-Chavez R, Solorza-Luna G, Villa-Trevino S, Arenas-Huertero F . Matrix metalloproteinases-2, -3, and -9 secreted by explants of benign and malignant lesions of the uterine cervix. Int J Gynecol Cancer. 2004; 14(2):333-40. DOI: 10.1111/j.1048-891x.2004.014218.x. View

Chang H, Liu L, Hung W . Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. Cell Signal. 2004; 16(6):675-9. DOI: 10.1016/j.cellsig.2003.11.001. View

10.

Shimamura T, Yasuda J, Ino Y, Gotoh M, Tsuchiya A, Nakajima A . Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells. Cancer Res. 2004; 64(19):6989-95. DOI: 10.1158/0008-5472.CAN-04-1166. View

11.

Guo D, Zhang J, Yuen S, Tsui W, Chan A, Ho C . Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis. 2005; 27(3):454-64. DOI: 10.1093/carcin/bgi259. View

12.

Valster A, Tran N, Nakada M, Berens M, Chan A, Symons M . Cell migration and invasion assays. Methods. 2005; 37(2):208-15. DOI: 10.1016/j.ymeth.2005.08.001. View

13.

Overall C, Dean R . Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev. 2006; 25(1):69-75. DOI: 10.1007/s10555-006-7890-0. View

14.

Chen C, Sung J, Cohen M, Chowdhury W, Sachs M, Li Y . Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J Pharmacol Exp Ther. 2006; 319(2):533-42. DOI: 10.1124/jpet.106.106658. View

15.

Hellebrekers D, Griffioen A, van Engeland M . Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta. 2006; 1775(1):76-91. DOI: 10.1016/j.bbcan.2006.07.003. View

16.

Chang H, Cho C, Hung W . Silencing of the metastasis suppressor RECK by RAS oncogene is mediated by DNA methyltransferase 3b-induced promoter methylation. Cancer Res. 2006; 66(17):8413-20. DOI: 10.1158/0008-5472.CAN-06-0685. View

17.

Arce C, Perez-Plasencia C, Gonzalez-Fierro A, De La Cruz-Hernandez E, Revilla-Vazquez A, Chavez-Blanco A . A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One. 2006; 1:e98. PMC: 1762324. DOI: 10.1371/journal.pone.0000098. View

18.

Mora-Garcia M, Duenas-Gonzalez A, Hernandez-Montes J, De La Cruz-Hernandez E, Perez-Cardenas E, Weiss-Steider B . Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J Transl Med. 2006; 4:55. PMC: 1781077. DOI: 10.1186/1479-5876-4-55. View

19.

Cho C, Wang J, Chang H, Chang C, Hung W . Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells. J Cell Physiol. 2007; 213(1):65-9. DOI: 10.1002/jcp.21089. View

20.

Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay H . Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol. 2007; 212(2):330-44. DOI: 10.1002/jcp.21066. View